Haisco Inks Second Deal This Year With A Startup, Worth Up To $1.5bn-Plus
Haisco Pharmaceutical out-licensed a preclinical drug for inflammatory diseases to Sentivera for $75.89m up front, including a 17.5% stake in the startup backed by ARCH Venture Partners and Population Health Partners.
Scrip - August 25, 2026

B+L Sees Standard-Of-Care Potential For Dual-Acting Dry Eye Drop
Bausch + Lomb said its eye drop combining the active ingredients from Xiidra and Miebo will soon move into Phase III. The firm is also bullish on a Phase II ocular surface pain candidate.
Scrip - August 25, 2026

J&J’s Imaavy Chalks Up Another Win With Approval In wAIHA
The US FDA approval marks the second indication for the FcRn inhibitor after its April 2025 approval for generalized myasthenia gravis.
Scrip - August 25, 2026

Awaiting Second Blockbuster Approval, Protagonist Scales Up Its Peptide Ambitions
A pioneer of first-in-class oral peptide drugs, Protagonist has opted to let big pharma partners bring its first two products to market. CEO Dinesh Patel tells Scrip how it plans to use a rich royalty stream to challenge more injectable immunology and obesity blockbusters with its pills.
Scrip - August 25, 2026

Capricor Bets On Upper-Limb Pivot To Salvage Deramiocel As FDA Extends Review
The FDA's approval decision date on Capricor's deramiocel has shifted to November, but questions remain over whether fresh long-term HOPE-3 data and a refined upper-limb indication will be enough to convince the agency.
Scrip - August 25, 2026

Stock Watch: Rehabilitating Lost Pharmas
When a stock underperforms for years, investors often term them lost causes, rebased or dead money because it can take many years of positive events to recover. CSL and Bayer may have started on that journey.
Scrip - August 25, 2026

HUTCHMED Carves New Path For Biologics To Address Small Molecule Challenges
HUTCHMED’s Guangxiu Dai talks to Scrip about the firm’s rationale for building its portfolio of antibody-targeted therapy conjugates, and related clinical development strategies.
Scrip - August 25, 2026

Paradromics Gets FDA Approval To Embed BCI Software In Personal Devices
Paradromics gained FDA approval to expand its BCI access from research laptops to personal devices during clinical trials. Medtech Insight spoke with CCO William Marks about the implications of the new approval and progress of the first patient in the feasibility study to closed-loop stage.
Medtech Insight - August 26, 2026

Avon’s New Owner To Reunite Struggling North American Biz With International
Beverly Hills, Calif.-based Regent has agreed to purchase direct-sales brand Avon North America from Korean company LG Household & Health Care Ltd.
HBW Insight - August 25, 2026

Clear Eyes Recall Adds Another Bump On Road To Production, Sales Rebound For Prestige Consumer
Voluntary recall of 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief closely flowed PCH executives reporting progress in returning supplies of the brand to normal levels following setbacks linked to multiple production problems dating to 2024.
HBW Insight - August 25, 2026

Bayer Eyes GLP-1 Companion Play With Existing Portfolio And Metabolic Platform Ambitions
Exclusive: Bayer Consumer Health has staked its claim to the GLP-1 companion space, mapping existing brands to user symptoms and signaling an interest in developing “metabolic self-care platforms.”
HBW Insight - August 25, 2026

Difficult Transition Period Ahead For EU Med Devices Regulation After Notified Body Closures
Experts say lowered demand, staff shortages, and changes to MDR and IVDR are forcing a realignment of the notified body sector.
HBW Insight - August 25, 2026

CHPA CEO Looks Back On OMUFA As ‘Most Impactful’ Change Six Months Ahead Of Exit
“OMUFA 2020 was just an accomplishment that I will forever treasure. It was a casebook study on how policy making should be done. Congress, the administration, the FDA, the industry identified a problem and worked together to come up with solutions,” says CHPA president and CEO Scott Melville.
HBW Insight - August 25, 2026

Coty Replaces CFO; L’Oréal Appoints New DE&I Head: Beauty Leadership Roundup
Coty names Soraya Benchikh as CFO effective September 1, succeeding Laurent Mercier. Separately, L'Oréal USA promotes Rahquel Purcell, its former chief transformation officer, to chief diversity, equity & inclusion officer; Beauty Leadership Roundup
HBW Insight - August 25, 2026

Turkey Takes Teva To Task Over Copaxone Divisionals
An investigation into Teva has been launched by the Turkish Competition Authority, citing conduct intended to restrict competition for generics through the strategic use of divisional patents and creating a misleading impression of the efficacy and safety of competitors.
Generics Bulletin - August 25, 2026

US Courts Close Lipitor Antitrust Litigation, Favoring Sun Pharmaceuticals
A signature from a New Jersey district court judge has finalized a battle over a settlement agreement that represented over a decade of litigation.
Generics Bulletin - August 25, 2026

Alvotech Takes First Direct US Commercialization Step In $150m Lotus Deal
Alvotech has used a $150m Lotus deal to take its first step into direct US biosimilar commercialization, retaining rights to market two pipeline assets itself while preserving its established partner-led model.
Generics Bulletin - August 25, 2026

Big Pharma’s Revenue Mix Is Shifting Back Toward Homegrown Drugs
Big pharma's revenue mix is tilting back to homegrown drugs — organic assets hit 53% of top-15 sales by 2025. However, some firms are increasingly reliant on partnered or acquired products, while others face looming patent cliffs.
In Vivo - August 26, 2026